Moderator: Steven Burrell

Current indications and upcoming targets 
Patrick Veit-Haibach

This presentation will provide an overview about the basics of theranostics, including examples of the current trial landscape and an outlook on upcoming/currently debated targets.

At the end of this presentation, participants will be able to:

• Describe the fundamentals of theranostics, including its applications in personalized medicine.
• Review the most relevant ongoing trials and summarize the current results in theranostics.
• Identify the key emerging targets for theranostic trials and discuss their potential impact on clinical practice.

Target Audience:

• Radiologist

CanMEDS:

• Medical Expert
• Collaborator
• Leader
• Professional

The speaker discloses the following relationships:

• Receipt of IIS grants from Bayer Switzerland, Roche Pharmaceuticals, Siemens Healthineers, and GE Healthcare.
• Participation in industry-sponsored theranostic trials, including Novartis, RayzeBio, and Fusion.
• Service on the advisory board for Novartis and Eli Lilly.
• Receipt of IIS trial support from Pentixapharm and Siemens Healthineers.
• Receipt of speaker fees and travel support from Siemens Healthineers and GE Healthcare.
• Receipt of speaker fees from the Ontario Association of Radiologists, JCA PET/CT course, Taiwan Oncology Society, Astellas, and Novartis.
• Receipt of editor fees from Springer Nature.
• Receipt of reviewer compensation from Wellcome Trust.
• Receipt of strategic panel advisory compensation and travel support from the German Cancer Center.

- - -

Expanding Access to Theranostics and Implementing Precision Oncology: Experience from a Comprehensive Vertically Integrated Theranostics Center
Harshad Kulkarni

This session highlights the operational and clinical framework of a comprehensive, vertically integrated theranostics center. Using the BAMF Health model, the discussion will focus on expanding access to precision oncology, addressing barriers in community and private settings, and advancing clinical research through novel radiopharmaceutical trials. Participants will gain actionable insights into optimizing care delivery, fostering collaborations, and driving innovation in theranostics.

At the end of this presentation, participants will be able to:

• Describe the key components of a vertically integrated theranostics center and their role in delivering personalized care through molecular imaging, targeted radionuclide therapy, and advanced radiopharmacy services.
• Identify strategies to overcome barriers in community settings and explore opportunities for implementing and participating in novel radiopharmaceutical clinical trials to drive innovation and expand treatment options.
• Discuss how comprehensive theranostics centers can enhance patient outcomes by integrating diagnostics with therapeutics and collaborating with healthcare providers, industry, and research organizations.

Target Audience:

• Radiologist
• Resident
• Medical Student

CanMEDS:

• Medical Expert
• Communicator
• Collaborator
• Leader
• Health Advocate
• Scholar
• Professional

The speaker discloses the following relationships:

• Employment with BAMF Health.
• Receipt of an honorarium from GE Healthcare.
• Service on advisory boards for Novartis and GE Healthcare.
• Participation in speakers' bureaus for United Imaging and ITM.
• Recipient of a funded grant from United Imaging.

- - -